吴豫生于2026年9月10日以每股均价2.9699港元买入同源康医药-B股份22.50万股,涉资约66.82万港元。
吴豫生此次增持前持有同源康医药-B好仓1.24亿股,占比32.59%;增持后持股量为1.24亿股,好仓比例升至32.65%。
吴豫生于2026年9月10日以每股均价2.9699港元买入同源康医药-B股份22.50万股,涉资约66.82万港元。
吴豫生此次增持前持有同源康医药-B好仓1.24亿股,占比32.59%;增持后持股量为1.24亿股,好仓比例升至32.65%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.